Overview
US Patent Agent Jobs in New York, United States at MENARINI Group
Title: US Patent Agent
Company: MENARINI Group
Location: New York, United States
US PATENT AGENT – PHARMA INDUSTRY
About the Opportunity
Join the Menarini Group, a leading international pharmaceutical company, as we look for an experienced US Patent Agent to join our team. This is a unique opportunity to play a key role in the growth of our company to new ambitious heights.
In this position, your work will directly contribute to the achievement of our business objectives, ensuring the Menarini Group’s intellectual property is robust and aligned with our strategic goals.
You will join our Global IP Team, reporting to Global Patent and Trademark Director, based in our Group’s HQ in Florence. This is a unique opportunity to broaden your professional horizons beyond US.
The role will align functionally to the Menarini Group IP team while being a member of the US Menarini Stemline organization.
Your Key Responsibilities
As our US Patent Agent, you will drive value by bridging science and law. Your daily impact will include:
- R&D Partnership: Proactively partner with R&D and CMC teams to identify and evaluate novel inventions, conducting initial patentability assessments.
- Portfolio Strategy: Strategically manage and develop the Menarini Group's global patent portfolio, collaborating closely with external patent counsel to ensure robust, comprehensive, and globally aligned patent protection.
- Business Development Support: Provide critical support for business development and M&A activities, including conducting Freedom-to-Operate (FTO) analyses, patent due diligence, and validity assessments.
- Contract Analysis: Provide technical support on the interpretation of patent and IP-related clauses within various agreements, including licensing, collaboration, and R&D contracts.
- Legal Defense: Collaborate with the Legal team and outside counsels in the strategic defense of Menarini Group's global patent portfolio in infringement and invalidity disputes and proceedings globally.
- Budget Management: Contribute to budget management by carefully planning patent expenses, efficiently managing external counsel relationships, and implementing cost containment strategies without compromising portfolio strength.
What We Are Looking For
To be successful in this role, you should bring the following qualifications and expertise:
Education & Certifications
- Admission: Admission to practice before the USPTO.
- Academic Background: Bachelor's degree or higher in a Life Science discipline such as Biology, Chemistry, or Biochemistry (Advanced degree preferred).
Experience & Knowledge
- Professional Experience: A minimum of 4+ years of dedicated experience as a patent agent, preferably within a pharma/biotech corporate setting or a specialized Intellectual Property law firm with focus on life science.
- US Patent Expertise: Expertise in US patent law, PCT filing procedures, and US prosecution practice.
- Global Perspective: Strong working knowledge of European (EP) patent law and other significant global patent systems.
Core Competencies
- Communication & Collaboration: Exceptional analytical, written, and verbal communication skills, with the ability to collaborate effectively across diverse internal functional teams (R&D, Legal, Commercial) and manage outside counsel relationships efficiently.
Please note: this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Menarini Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Base Salary Range of $190,000-$220,000. Menarini Stemline offers generous compensation and benefits packages, including Short-Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, colour, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.
Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entryinto the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
